OAM
TARO

Oppenheimer Asset Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Oppenheimer Asset Management’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-32
Closed -$4K – 1735
2017
Q1 		$4K Buy
+32
New +$3.54K ﹤0.01% 1610

Other funds holding TARO

MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FL
Fort LP Chevy Chase, Maryland $39.6M AUM 37.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Oppenheimer Asset Management's TARO Position: Q2 2017 in Review

Oppenheimer Asset Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2017, closing a stake of 32 shares — an estimated $4K sold.

Oppenheimer Asset Management first reported a position in TARO in Q1 2017 and held it in 1 quarter. The position peaked at $4K in Q1 2017. 140 funds tracked by Wall St. Rank hold TARO as of Q2 2017.

  • Oppenheimer Asset Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2017 after selling out during the quarter.
  • Oppenheimer Asset Management sold 32 Taro Pharmaceutical Industries Ltd. shares in Q2 2017, an estimated $4K.
  • Oppenheimer Asset Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2017 and held it in 1 quarter.
  • Oppenheimer Asset Management's Taro Pharmaceutical Industries Ltd. position peaked at $4K in Q1 2017.
  • 140 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2017.

Based on Oppenheimer Asset Management's 13F filing for Q2 2017, filed 9 Aug 2017.